United Kingdom

The healthcare sector in the UK and internationally continues to experience a period of dynamic change underpinned by significant legal reforms and devolution to the four British nations. As an owner, operator or service provider in this sector, you are facing a highly regulated environment combined with increased public scrutiny. With increasing opportunities for the private provision of healthcare along with an ageing population, but with shrinking public healthcare budgets, operating within the healthcare sector presents both challenges and opportunities.

We act for many prominent industry players, advising on matters in all areas of health and social care including significant corporate, insolvency and banking matters, as well as regulation, insurance, procurement and competition issues. Our track record includes several sales and acquisitions valued at over GBP 100m and a number of PPP/PFI projects valued in excess of GBP 50m.

We have also built up a reputation for advising on innovative models of healthcare provision, such as managed services. Our expertise includes advising on collaborations with the NHS and with other organisations.

Long-standing clients include Nuffield Health, Sovereign Capital Partners, Spire Healthcare, IAC Investments LLP, John Laing, RBS Healthcare team, Lloyds Bank plc, Lloyds Development Capital, the National Fostering Agency, LGV Capital, Balfour Beatty plc, MML Capital, Bupa, Octopus Investments and Bridges Ventures.

Read more Read less
High­lights of our ex­per­i­ence in Health­care in the UK
Law-Now: Health­care
Vis­it Law-Now for leg­al know-how and com­ment­ary


Show only
CJEU re­fuses to shed light on third party SPC po­s­i­tion based on hy­po­thet­ic­al...
In­tro­duc­tion Fol­low­ing re­fer­ral from the High Court of Eng­land and Wales, the Court of Justice of the European Uni­on (the “CJEU”) re­fused to give a pre­lim­in­ary rul­ing on wheth­er a pat­entee can ob­tain a Sup­ple­ment­ary Pro­tec­tion Cer­ti­fic­ate (“SPC”) on the basis.
NICE draft re­com­mend­a­tions on medi­cin­al can­nabis
On 8 Au­gust 2019, the Na­tion­al In­sti­tute for Health & Care Ex­cel­lence (NICE) pub­lished draft guid­ance on pre­scrib­ing can­nabis-based medi­cin­al products for con­sulta­tion (Guid­ance). The Guid­ance will re­place in­ter­im clin­ic­al guid­ance is­sued by spe­cial­ist med­ic­al.